Dr. Sebastian Dorn

Establishment, Qualification and Validation of Immunogenicity assays Anti-Drug antibodies, neutralizing Antibodies, Affinity, ELISPOT, Bioplex assays Outsourcing of assays, CRO management, planing of budget, planing of ressources Performance of immungenicity assessment Head of GLP, GCLP Laboratories Immunogenicity Project Lead

assurance and establishment of quality standards for methods and reporting systems in preclinical research, diagnostics and clinical studies (GLP, GCLP) and production (GMP). responsible for GLP trainings, creations and approval of GLP/GCLP SOPs and performance of study, facility-based and external audits. preparation, handling and reporting of authority inspections and customer audits (GMP, AAALAC, ISO, FDA, AGES, etc.)

Focus on linear ubiquitation to efficiently upregulate NF-κB signaling as a consequence of TRAIL treatment in cancer cells, leading to potential higher therapeutic resistance. Development, advancement and leadership of additional cancer based projects (i.e. new virus vector for cancer, inhibition of mTOR pathway and HIF1-α, synthetic lethality by knockdown of lethal genes) in an interdisciplinary research team. Identification of predictive and pharmacodynamics biomarkers for potential therapies.